Daniel Baker

7.3k total citations · 2 hit papers
72 papers, 5.2k citations indexed

About

Daniel Baker is a scholar working on Orthopedics and Sports Medicine, Rheumatology and Hematology. According to data from OpenAlex, Daniel Baker has authored 72 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Orthopedics and Sports Medicine, 27 papers in Rheumatology and 19 papers in Hematology. Recurrent topics in Daniel Baker's work include Sports Performance and Training (30 papers), Sports injuries and prevention (21 papers) and Rheumatoid Arthritis Research and Therapies (21 papers). Daniel Baker is often cited by papers focused on Sports Performance and Training (30 papers), Sports injuries and prevention (21 papers) and Rheumatoid Arthritis Research and Therapies (21 papers). Daniel Baker collaborates with scholars based in United States, Australia and Germany. Daniel Baker's co-authors include Désirée van der Heijde, Jürgen Braun, Robert Landewé, Pedro Machado, Greg J. Wilson, Robert U. Newton, Michael P. Moore, Tore K Kvien, E. Lie and Xenofon Baraliakos and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Daniel Baker

70 papers receiving 4.9k citations

Hit Papers

Ankylosing Spondylitis Di... 2010 2026 2015 2020 2010 2023 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores
    2010 549 citations Pedro Machado, Robert Landewé et al. Annals of the Rheumatic Diseases profile →
  2. CAR T therapy beyond cancer: the evolution of a living drug
    2023 286 citations Daniel Baker, Zoltàn Arany et al. Nature profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Daniel Baker 2.5k 2.2k 1.3k 1.0k 985 72 5.2k
Thomas M. Zizic 1.2k 0.5× 1.2k 0.5× 177 0.1× 110 0.1× 92 0.1× 31 2.8k
Ken Okazaki 915 0.4× 624 0.3× 302 0.2× 563 0.6× 160 0.2× 271 4.8k
B. Swoboda 1.6k 0.6× 499 0.2× 100 0.1× 338 0.3× 65 0.1× 105 2.8k
I.K. Haugen 3.2k 1.3× 566 0.3× 125 0.1× 271 0.3× 110 0.1× 208 4.1k
Feng Huang 2.1k 0.9× 211 0.1× 1.2k 1.0× 34 0.0× 827 0.8× 102 3.0k
Jean‐Pierre Raynauld 2.3k 0.9× 475 0.2× 162 0.1× 418 0.4× 138 0.1× 58 3.4k
Brian Dawson 561 0.2× 243 0.1× 116 0.1× 109 0.1× 34 0.0× 43 1.9k
Kristian Stengaard‐Pedersen 1.2k 0.5× 519 0.2× 1.1k 0.8× 38 0.0× 403 0.4× 119 3.4k
John P. Case 1.4k 0.6× 158 0.1× 201 0.2× 857 0.8× 136 0.1× 23 2.8k
Christoph Weiler 484 0.2× 257 0.1× 414 0.3× 449 0.4× 200 0.2× 45 3.3k

Countries citing papers authored by Daniel Baker

Since Specialization
Citations

This map shows the geographic impact of Daniel Baker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Baker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Baker more than expected).

Fields of papers citing papers by Daniel Baker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Baker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Baker. The network helps show where Daniel Baker may publish in the future.

Co-authorship network of co-authors of Daniel Baker

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Baker. A scholar is included among the top collaborators of Daniel Baker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Baker. Daniel Baker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Baker, Daniel, Bruce L. Levine, & Carl H. June. (2025). Assessing the oncogenic risk: the long-term safety of autologous chimeric antigen receptor T cells. The Lancet. 405(10480). 751–754. 5 indexed citations
2.
Baker, Daniel & Carl H. June. (2024). Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases. Cell. 187(18). 4826–4828. 12 indexed citations
3.
Baker, Daniel, Zoltàn Arany, Joseph A. Baur, Jonathan A. Epstein, & Carl H. June. (2023). CAR T therapy beyond cancer: the evolution of a living drug. Nature. 619(7971). 707–715. 286 indexed citations breakdown →
4.
Emery, Paul, Roy Fleischmann, Elizabeth C. Hsia, et al.. (2014). Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis. Clinical Rheumatology. 33(9). 1239–1246. 8 indexed citations
5.
Machado, Pedro, Robert Landewé, Jürgen Braun, et al.. (2012). MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Annals of the Rheumatic Diseases. 71(12). 2002–2005. 68 indexed citations
6.
7.
Heijde, Désirée van der, Pedro Machado, Jürgen Braun, et al.. (2011). MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases. 71(3). 369–373. 100 indexed citations
8.
9.
Baker, Daniel. (2009). German volume training: An alternative method of high volume-load training for stimulating muscle growth. Australasian Journal of Paramedicine. 20(4). 64–67. 4 indexed citations
10.
Elliott, Michael R., Jacqueline Benson, Marion Blank, et al.. (2009). Ustekinumab: Lessons Learned from Targeting Interleukin‐12/23p40 in Immune‐Mediated Diseases. Annals of the New York Academy of Sciences. 1182(1). 97–110. 66 indexed citations
11.
Heijde, Désirée van der, Robert Landewé, Xenofon Baraliakos, et al.. (2008). Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis & Rheumatism. 58(10). 3063–3070. 380 indexed citations
12.
Zhou, Honghui, Haishan Jang, Roy Fleischmann, et al.. (2007). Pharmacokinetics and Safety of Golimumab, a Fully Human Anti‐TNF‐α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis. The Journal of Clinical Pharmacology. 47(3). 383–396. 149 indexed citations
13.
Strusberg, Ingrid, Piet Geusens, David E. Yocum, et al.. (2007). Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 66(9). 1233–1238. 91 indexed citations
14.
Visvanathan, Sudha, Carrie Wagner, Joseph C. Marini, et al.. (2007). Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Annals of the Rheumatic Diseases. 67(4). 511–517. 111 indexed citations
15.
Smolen, Josef S, Désirée van der Heijde, E. William St. Clair, et al.. (2006). Predictors of joint damage in patients with early rheumatoid arthritis treated with high‐dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial. Arthritis & Rheumatism. 54(3). 702–710. 342 indexed citations
16.
Visvanathan, Sudha, Carrie Wagner, Josef S Smolen, et al.. (2006). IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Arthritis & Rheumatism. 54(9). 2840–2844. 8 indexed citations
17.
Baker, Daniel. (2003). Acute Negative Effect of a Hypertrophy-Oriented Training Bout on Subsequent Upper-Body Power Output. The Journal of Strength and Conditioning Research. 17(3). 527–527. 18 indexed citations
18.
Baker, Daniel. (2003). Acute Effect of Alternating Heavy and Light Resistances on Power Output During Upper-Body Complex Power Training. The Journal of Strength and Conditioning Research. 17(3). 493–493. 119 indexed citations
19.
Baker, Daniel, et al.. (1994). Generality versus specificity: a comparison of dynamic and isometric measures of strength and speed-strength. European Journal of Applied Physiology. 68(4). 350–355. 189 indexed citations
20.
Rabinowitz, Joseph L., et al.. (1986). Comparison of fatty acid patterns of polar and neutral lipid classes and cyclo-oxygenase activity in taste and non-taste epithelium of steer tongues. International Journal of Biochemistry. 18(6). 543–548. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas M. Zizic Breakdown of academic impact, for papers by Ken Okazaki Breakdown of academic impact, for papers by B. Swoboda Breakdown of academic impact, for papers by I.K. Haugen Breakdown of academic impact, for papers by Feng Huang Breakdown of academic impact, for papers by Jean‐Pierre Raynauld Breakdown of academic impact, for papers by Brian Dawson Breakdown of academic impact, for papers by Kristian Stengaard‐Pedersen Breakdown of academic impact, for papers by John P. Case Breakdown of academic impact, for papers by Christoph Weiler
Rankless by CCL
2026